Work

Carfilzomib, Lenalidomide and Dexamethasone (KRd) Vs Bortezomib, Lenalidomide, and Dexamethasone (VRd) As Induction Therapy in Newly Diagnosed High-Risk Multiple Myeloma

Year: 2022

Type: article

Study design: Observational Study

Source: Blood

DOI: 10.1182/blood-2022-169161

Authors: Carlyn Tan, David Nemirovsky, Andriy Derkach, Malin Hultcrantz, Hani Hassoun, Sham Mailankody, Urvi A Shah, Dhwani Patel, Kylee H Maclachlan, Oscar B Lahoud, Gunjan L. Shah, Michael Scordo, David J. Chung, Heather Landau, Sergio A Giralt, Alexander M Lesokhin, Neha Korde, Saad Usmani

Institution: Memorial Sloan Kettering Cancer Center

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4310112300

FWCI: 0.626

Cites:

Cited by: 5

Related to: 10